Apolipoprotein C-III in triglyceride-rich lipoprotein metabolism
B Ramms, PLSM Gordts - Current opinion in lipidology, 2018 - journals.lww.com
B Ramms, PLSM Gordts
Current opinion in lipidology, 2018•journals.lww.comNovel in vivo models and APOC3 missense variants revealed unique mechanisms by which
apoC-III inhibits TRL catabolism. Clinical trials with Volanesorsen, an APOC3 antisense
oligonucleotide, report very promising lipid-lowering outcomes. However, future studies will
need to address if acute apoC-III lowering will have the same clinical benefits as a life-long
reduction.
apoC-III inhibits TRL catabolism. Clinical trials with Volanesorsen, an APOC3 antisense
oligonucleotide, report very promising lipid-lowering outcomes. However, future studies will
need to address if acute apoC-III lowering will have the same clinical benefits as a life-long
reduction.
Summary
Novel in vivo models and APOC3 missense variants revealed unique mechanisms by which apoC-III inhibits TRL catabolism. Clinical trials with Volanesorsen, an APOC3 antisense oligonucleotide, report very promising lipid-lowering outcomes. However, future studies will need to address if acute apoC-III lowering will have the same clinical benefits as a life-long reduction.
Lippincott Williams & Wilkins